Annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis B virus infection

A population-based analysis

Fu Hsiung Su, Ya Li Huang, Fung Chang Sung, Chien Tien Su, Wen Hsin Hsu, Shih Ni Chang, Chih Ching Yeh

研究成果: 雜誌貢獻文章

1 引文 (Scopus)

摘要

Background: This study evaluated hospitalization and mortality in patients with chronic hepatitis B virus infection (HBV (+)) and matched comparison patients after stratifying the patients according to annual influenza vaccination (Vaccine (+)). Methods: Data from Taiwan's National Health Insurance program from 2000 to 2009 were used to identify HBV(+)/vaccine(+) (n=4434), HBV(+)/Vaccine(-) (n=3646), HBV(-)/Vaccine(+) (n=8868), and HBV(-)/Vaccine(-) (n=8868) cohorts. The risk of pneumonia/influenza, respiratory failure, intensive care, hospitalization, and mortality in the four cohorts was evaluated. Results: The total hospitalization rate was significantly lower in patients with chronic HBV infection who received an annual influenza vaccination than in chronic HBV-infected patients who did not receive an influenza vaccination (16.29 vs. 24.02 per 100 person-years), contributing to an adjusted hazard ratio (HR) of 0.56 (95% confidence interval (CI). =0.50-0.62). The HBV(+)/Vaccine(+) cohort also had lower risks than the HBV(+)/Vaccine(-) cohort for pneumonia and influenza (adjusted HR. =0.79, 95% CI. =0.67-0.92), intensive care unit admission (adjusted HR. =0.33, 95% CI. =0.25-0.43), and mortality (adjusted HR. =0.19, 95% CI. =0.15-0.24). Conclusions: Our results suggest that annual influenza vaccination can reduce the risk of hospitalization and mortality in patients with chronic HBV infection.
原文英語
頁(從 - 到)120-127
頁數8
期刊Vaccine
34
發行號1
DOIs
出版狀態已發佈 - 一月 2 2016

指紋

chronic hepatitis B
Hepatitis B virus
Chronic Hepatitis B
Virus Diseases
influenza
Human Influenza
Vaccination
Hospitalization
Vaccines
vaccination
vaccines
confidence interval
infection
Confidence Intervals
Population
Mortality
National Health Programs
Pneumonia
pneumonia
Influenza Vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

引用此文

Annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis B virus infection : A population-based analysis. / Su, Fu Hsiung; Huang, Ya Li; Sung, Fung Chang; Su, Chien Tien; Hsu, Wen Hsin; Chang, Shih Ni; Yeh, Chih Ching.

於: Vaccine, 卷 34, 編號 1, 02.01.2016, p. 120-127.

研究成果: 雜誌貢獻文章

@article{d346a02e9ed34470a06ab46864c79fac,
title = "Annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis B virus infection: A population-based analysis",
abstract = "Background: This study evaluated hospitalization and mortality in patients with chronic hepatitis B virus infection (HBV (+)) and matched comparison patients after stratifying the patients according to annual influenza vaccination (Vaccine (+)). Methods: Data from Taiwan's National Health Insurance program from 2000 to 2009 were used to identify HBV(+)/vaccine(+) (n=4434), HBV(+)/Vaccine(-) (n=3646), HBV(-)/Vaccine(+) (n=8868), and HBV(-)/Vaccine(-) (n=8868) cohorts. The risk of pneumonia/influenza, respiratory failure, intensive care, hospitalization, and mortality in the four cohorts was evaluated. Results: The total hospitalization rate was significantly lower in patients with chronic HBV infection who received an annual influenza vaccination than in chronic HBV-infected patients who did not receive an influenza vaccination (16.29 vs. 24.02 per 100 person-years), contributing to an adjusted hazard ratio (HR) of 0.56 (95{\%} confidence interval (CI). =0.50-0.62). The HBV(+)/Vaccine(+) cohort also had lower risks than the HBV(+)/Vaccine(-) cohort for pneumonia and influenza (adjusted HR. =0.79, 95{\%} CI. =0.67-0.92), intensive care unit admission (adjusted HR. =0.33, 95{\%} CI. =0.25-0.43), and mortality (adjusted HR. =0.19, 95{\%} CI. =0.15-0.24). Conclusions: Our results suggest that annual influenza vaccination can reduce the risk of hospitalization and mortality in patients with chronic HBV infection.",
keywords = "Hepatitis B virus, Influenza, Population-based study, Vaccination",
author = "Su, {Fu Hsiung} and Huang, {Ya Li} and Sung, {Fung Chang} and Su, {Chien Tien} and Hsu, {Wen Hsin} and Chang, {Shih Ni} and Yeh, {Chih Ching}",
year = "2016",
month = "1",
day = "2",
doi = "10.1016/j.vaccine.2015.10.129",
language = "English",
volume = "34",
pages = "120--127",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Annual influenza vaccination reduces total hospitalization in patients with chronic hepatitis B virus infection

T2 - A population-based analysis

AU - Su, Fu Hsiung

AU - Huang, Ya Li

AU - Sung, Fung Chang

AU - Su, Chien Tien

AU - Hsu, Wen Hsin

AU - Chang, Shih Ni

AU - Yeh, Chih Ching

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Background: This study evaluated hospitalization and mortality in patients with chronic hepatitis B virus infection (HBV (+)) and matched comparison patients after stratifying the patients according to annual influenza vaccination (Vaccine (+)). Methods: Data from Taiwan's National Health Insurance program from 2000 to 2009 were used to identify HBV(+)/vaccine(+) (n=4434), HBV(+)/Vaccine(-) (n=3646), HBV(-)/Vaccine(+) (n=8868), and HBV(-)/Vaccine(-) (n=8868) cohorts. The risk of pneumonia/influenza, respiratory failure, intensive care, hospitalization, and mortality in the four cohorts was evaluated. Results: The total hospitalization rate was significantly lower in patients with chronic HBV infection who received an annual influenza vaccination than in chronic HBV-infected patients who did not receive an influenza vaccination (16.29 vs. 24.02 per 100 person-years), contributing to an adjusted hazard ratio (HR) of 0.56 (95% confidence interval (CI). =0.50-0.62). The HBV(+)/Vaccine(+) cohort also had lower risks than the HBV(+)/Vaccine(-) cohort for pneumonia and influenza (adjusted HR. =0.79, 95% CI. =0.67-0.92), intensive care unit admission (adjusted HR. =0.33, 95% CI. =0.25-0.43), and mortality (adjusted HR. =0.19, 95% CI. =0.15-0.24). Conclusions: Our results suggest that annual influenza vaccination can reduce the risk of hospitalization and mortality in patients with chronic HBV infection.

AB - Background: This study evaluated hospitalization and mortality in patients with chronic hepatitis B virus infection (HBV (+)) and matched comparison patients after stratifying the patients according to annual influenza vaccination (Vaccine (+)). Methods: Data from Taiwan's National Health Insurance program from 2000 to 2009 were used to identify HBV(+)/vaccine(+) (n=4434), HBV(+)/Vaccine(-) (n=3646), HBV(-)/Vaccine(+) (n=8868), and HBV(-)/Vaccine(-) (n=8868) cohorts. The risk of pneumonia/influenza, respiratory failure, intensive care, hospitalization, and mortality in the four cohorts was evaluated. Results: The total hospitalization rate was significantly lower in patients with chronic HBV infection who received an annual influenza vaccination than in chronic HBV-infected patients who did not receive an influenza vaccination (16.29 vs. 24.02 per 100 person-years), contributing to an adjusted hazard ratio (HR) of 0.56 (95% confidence interval (CI). =0.50-0.62). The HBV(+)/Vaccine(+) cohort also had lower risks than the HBV(+)/Vaccine(-) cohort for pneumonia and influenza (adjusted HR. =0.79, 95% CI. =0.67-0.92), intensive care unit admission (adjusted HR. =0.33, 95% CI. =0.25-0.43), and mortality (adjusted HR. =0.19, 95% CI. =0.15-0.24). Conclusions: Our results suggest that annual influenza vaccination can reduce the risk of hospitalization and mortality in patients with chronic HBV infection.

KW - Hepatitis B virus

KW - Influenza

KW - Population-based study

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84949730237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949730237&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.10.129

DO - 10.1016/j.vaccine.2015.10.129

M3 - Article

VL - 34

SP - 120

EP - 127

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -